The fibrinogen αC region promotes arterial thrombosis in the context of hypofibrinogenemia
Authors:
- Robert H. LeeRLRobert H. Lee
- Alexander CouzensACAlexander Couzens
- Angelica Taylor JamesonAJAngelica Taylor Jameson
- Haley Elizabeth HanesHHHaley Elizabeth Hanes
- Alessandro CasiniACAlessandro Casini
- Marguerite Neerman-ArbezMNMarguerite Neerman-Arbez
- Wolfgang BergmeierWBWolfgang Bergmeier
- Matthew J. FlickMFMatthew J. Flick
- Woosuk Steve HurWHWoosuk Steve Hur
Open Access
- 4 June 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 147 (23) , 2821-2827
Abstract
Hypofibrinogenemia reduces experimental venous thrombosis, but the impact on arterial thrombosis remains unknown. In a cohort of patients with congenital fibrinogen disorders, 19 of 264 (∼7%) patients developed arterial thrombosis, including 4 of 41 (∼10%) patients with hypofibrinogenemia. However, 0 of 8 patients with fibrinogen αC-region truncation mutations reported arterial thrombosis over 286 patient-years. To analyze the impact of hypofibrinogenemia and the fibrinogen αC region on arterial thrombosis, 2 mouse models were employed: (1) wild-type mice treated with lipid nanoparticles encapsulating small interfering RNA against fibrinogen (siFga) and (2) Fga270/270 hypofibrinogenemic mice expressing fibrinogen with a truncated αC region. Although siFga-treated hypofibrinogenemic mice developed occlusive carotid artery thrombi similarly to controls, Fga270/270 mice displayed suppressed carotid thrombosis following FeCl3 challenge, indicating loss of the αC region but not hypofibrinogenemia alone reduces arterial thrombosis. To determine if protection from arterial thrombosis in Fga270/270 mice was linked to loss of αC-region–platelet glycoprotein VI receptor (GPVI) interaction, platelet GPVI was depleted by JAQ1 antibody administration. JAQ1-treated wild-type mice were protected from arterial thrombosis following 5% FeCl3 but not 10% FeCl3 challenge. Interestingly, JAQ1 administration suppressed arterial thrombosis in siFga-treated mice but did not enhance protection in Fga270/270 mice following 10% FeCl3 challenge. Our studies suggest the fibrinogen αC region promotes arterial thrombosis in hypofibrinogenemic conditions.Keywords
This publication has 21 references indexed in Scilit:
- The humanized platelet glycoprotein VI Fab inhibitor EMA601 protects from arterial thrombosis and ischaemic stroke in miceEuropean Heart Journal, 2024
- The Global Burden of Cardiovascular Diseases and RiskJACC, 2022
- Heterogeneity of congenital afibrinogenemia, from epidemiology to clinical consequences and managementBlood Reviews, 2021
- GPVI (Glycoprotein VI) Interaction With Fibrinogen Is Mediated by Avidity and the Fibrinogen αC-RegionArteriosclerosis, Thrombosis, and Vascular Biology, 2021
- Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019JACC, 2020
- The distinctive structure and composition of arterial and venous thrombi and pulmonary emboliScientific Reports, 2020
- Fibrinogen αC domain: Its importance in physiopathologyResearch and Practice in Thrombosis and Haemostasis, 2019
- Functional significance of the platelet immune receptors GPVI and CLEC-2Journal of Clinical Investigation, 2019
- Long-Term Antithrombotic Protection by in Vivo Depletion of Platelet Glycoprotein VI in MiceJournal of Experimental Medicine, 2001
- Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice.Genes & Development, 1995